Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stopping etanercept after remission in juvenile idiopathic arthritis
NL-OMON34350Phase 4Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jan 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of etanercept in juvenile idiopathic arthritis (JIA) (2 arms), sponsored by Erasmus MC. Primary endpoints: Flare rate and Prediction model for successful discontinuation. Started Jan 2011; status: active, not recruiting.
02
Drugs
etanercept
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on NL-OMON34350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34350.